To study the dependence of bleomycin acute injury on WBCs, rabbits (n=4) were given 10 units/kg of bleomycin after depletion of granulated WBCs by nitrogen mustard. A marked reduction in injury was seen (day 8 PaC\, 25.8 ±1.8 mm Hg for bleomycin vs 53.5 ±6.8 mm Hg for bleomycin with WBC depletion).
B
leomycin, an antineoplastic compound, is used therapeutically against a variety of squamous cell carcinoma and lymphomas. 1 A dose-and time-dependent pulmonary toxicity develops that progresses to pulmonary fibrosis in approximately 1% of patients. 1 Intratracheal bleomycin is widely used to produce an animal model for the study of pulmonary fibrosis. 2, 3 The cytotoxicity of bleomycin has been suggested to be related to a ferrous iron-molecular oxygen mechanism that induces intracellular DNA chain breakage. 4 Furthermore, studies have shown that bleomycin produces superoxide and hydroxyl radicals and initiates lipid peroxidation in the presence of iron and oxygen. 45 Although bleomycin-induced pulmonary fibrosis has been investigated biochemically and morphologically, its mechanism has not been established. 2, 3 It is believed that lipid peroxidation might be related to the pulmonary fibrosis, but involvement of the inflammatory and immune systems has also been suggested. 3,6,7 Therefore, iron-catalyzed oxygen radical formation and lipid peroxidation might participate in bleomycininduced pulmonary fibrosis.
We examined the effect of deferoxamine, a ferric iron chelator, on the severity of bleomycin-induced pulmonary fibrosis to evaluate the possible role of ferric iron. Our results
show that there was a significant decrease in biochemical and morphologic indicators of bleomycin-induced pulmonary fibrosis following deferoxamine treatment. harvested. 2 Right lung was dissected free of all major structures and used for collagen determination. 8 Left lung was then filled with 10% Millonig's buffered formalin via the trachea at a constant pressure of 25 cm H2Ofor24 hours. The tissue was embedded in paraffin and5u, coronal sections cut, mounted on glass slides and stained with hematoxylin and eosin (H & E). The severity of lesions in these sections was graded using a modification of the criteria described by Szapiel et al. 8 Hydroxyproline determination was performed on the right lung using the colorimetric assay as described previously. 5 
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The effect of intratracheal bleomycin with and without deferoxamine on body weight are shown in Table 1 . The SAL-SAL group and the SAL-DF group attained 120.8% and 120.6% of their initial body weight, respectively, in 21 days.
The BLEO-DF group exhibited a weight gain to 104.5% of their initial body weight. There were no significant differences between these groups. In contrast, the BLEO-SAL group showed a significant weight loss to 95.0% of its initial body weight compared with either the SAL-SAL or SAL-DF group.
The 21-day cumulative mortality for the hamsters in various treatment groups are shown in Table 1 . The mortality rate in the bleomycin groups was 60%; there appears to be no direct or synergistic effect of deferoxamine on mortality. Deferoxamine also has been reported to modulate directly fibroblast proliferation and collagen synthesis. In 24-day cultured lung fibroblasts, deferoxamine was shown to decrease proliferation and prolyl hydroxylase activity. 19 However, in an earlier study, prolyl hydroxylase activity was stimulated by deferoxamine. 20 It appears that the effect of deferoxamine on prolyl hydroxylase activity is controversial.
Bleomycin-induced pulmonary fibrosis is reduced by parenteral deferoxamine as determined by lung hydroxyproline content and lesion severity. The mechanism by which deferoxamine is acting to reduce lung injury in unknown. However, deferoxamine's effect on hydroxyl radical formation and lipid peroxidation, as well as possible secondary effects on lymphocyte proliferation, might contribute to the decrease in bleomycin-induced pulmonary fibrosis.
